Aravive
Houston, US · Texas corporation · 3 known investors
Find your way into Aravive
118 people in our graph share verified history with the Aravive team — schools, employers, funds. One of them is your warm intro.
Jonathan Burbaumunlockedknows Jay Shepard · together at Sofinnova Ventures (overlapped)
×10knows the team · via Sofinnova Ventures
knows the team · via JDRF T1D Fund
Founders & leadership
AG
Amato GiacciaFounder
RH
Rudy HowardChief Financial Officer
RB
Robert B. GellerinChief Medical Officer
GM
Gail McIntyreChief Executive Officer
LS
Leonard Scott DoveChief Operating Officer
JB
Joshua BrummExecutive
JS
Jay ShepardinExecutiveJay Shepard held executive and CEO roles at multiple pharmaceutical companies including NextWave Pharmaceuticals (acquired by Pfizer), Ilypsa (acquired by Amgen), and Versartis, which merged with Aravive in 2018. He spent over 35 years in pharmaceutical and biotechnology leadership, with experience spanning drug development, commercial operations, and product launches.
JC
Jeffrey ClelandExecutive
PW
Paul WestbergExecutive
SC
Sigurd C. KirkNamed on SEC filing
MW
Michael W. RogersNamed on SEC filing
PT
Peter T.C. HoNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$106.6M disclosed across 3 rounds · 2014–2022
▶$41.6MraisedOct 2022 · 17 investors · BiotechnologyRule 506(b)
▶$41.6MraisedOct 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rudy HowardExecutive Officer
- Fredric N. EshelmanExecutive Officer, Director
- Sigurd C. KirkDirector
- Michael W. RogersDirector
- Peter T.C. HoDirector
- Robert B. GellerExecutive Officer
- Gail McIntyreExecutive Officer, Director
- Leonard Scott DoveExecutive Officer
- Eric ZhangDirector
- Amato GiacciaDirector
- John A. HohneckerDirector
- Offering amount
- $41.6M
- Amount sold
- $41.6M
- Sales commissions
- $1.1M
- Placement agents
- MTS Securities, LLC
- First sale
- Oct 2022
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$55MraisedFeb 2014 · 19 investors · BiotechnologyRule 506(b)
▶$55MraisedFeb 2014 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael DybbsDirector
- Shahzad MalikDirector
- Srinivas AkkarajuDirector
- Jeffrey ClelandExecutive Officer, Director
- Anthony SunDirector
- Francesco De RubertisDirector
- Joshua BrummExecutive Officer
- Edmon JenningsDirector
- Jay ShepardDirector
- Paul WestbergExecutive Officer
- Offering amount
- $55M
- Amount sold
- $55M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedFeb 2014 · 10 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony SunDirector
- Joshua BrummExecutive Officer
- Jay ShepardDirector
- Shahzad MalikDirector
- Edmon JenningsDirector
- Francesco De RubertisDirector
- Srinivas AkkarajuDirector
- Jeffrey ClelandExecutive Officer, Director
- Paul WestbergExecutive Officer
- Michael DybbsDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who founded Aravive?
- Aravive was founded by Amato Giaccia.
- Who are Aravive's investors?
- Aravive's investors include 3E Bioventures Capital, Advent Life Sciences, Eshelman Ventures, LLC.
- How much funding has Aravive raised?
- Aravive has disclosed $106.6M raised across 3 rounds.
- Where is Aravive headquartered?
- Aravive is headquartered in Houston, US.